MENU
Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related…
We use cookies to make your website experience better. By accepting this notice and continuing to browse our website you confirm you accept our Terms of Use & Privacy Policy.
read more >>
View Print Edition
View Digital Edition
View Special Edition